Conquering the barriers: are antibody therapeutics feasible for CNS indications?

Download
  1. Get@NRC: Conquering the barriers: are antibody therapeutics feasible for CNS indications? (Opens in a new window)
DOIResolve DOI: http://doi.org/10.2217/fnl.15.3
AuthorSearch for: ; Search for:
TypeArticle
Journal titleFuture Neurology
ISSN1479-6708
Volume10
Issue2
Pages6770; # of pages: 4
SubjectCNS therapeutics; blood–brain barrier; drug development
AbstractThe major hurdles on the development path of CNS therapeutics include an inherent complexity of the CNS, highly restricted drug access to CNS targets by the blood–brain barrier (BBB), paucity of translational preclinical disease models, safety risks, and lack of clinical biomarkers to aid in patient selection and early assessment of efficacy in clinical trials. Drug development for CNS is therefore highly complex and risky – more expensive and lengthy than for any other indication. The CNS drugs have one of the highest pipeline attrition rates and longest development times (114 months); clinical trial failures tend to occur later in the clinical development, making the cost of developing a CNS drug among the highest of any therapeutic indication.
Publication date
LanguageEnglish
AffiliationHuman Health Therapeutics; National Research Council Canada
Peer reviewedYes
NRC numberNRC-HHT-53292
NPARC number21275231
Export citationExport as RIS
Report a correctionReport a correction
Record identifieref1e9ba6-ccdc-43dd-85d7-b5bc0110d90f
Record created2015-05-26
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)